Business Description
Cambium Bio Ltd
ISIN : AU0000327769
Compare
Compare
Traded in other countries / regions
CMB.Australia IPO Date
2013-09-19Description
Cambium Bio Ltd, formerly Regeneus Ltd is a clinical-stage regenerative medicine company in Australia. The company develops a portfolio of cell-based therapies to address unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology, and dermatology diseases. The company uses stem cell and immuno-oncology technologies to develop cell-based therapies. The company's product pipeline consists of two platform technologies, Progenza and Sygenus, across three target therapeutic areas namely osteoarthritis, neuropathic pain, and skin wound healing.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.08 | |||||
Equity-to-Asset | -12.32 | |||||
Debt-to-Equity | -0.32 | |||||
Debt-to-EBITDA | 7.38 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -16.9 | |||||
3-Year EPS without NRI Growth Rate | -12.2 | |||||
3-Year FCF Growth Rate | 33.2 | |||||
3-Year Book Growth Rate | 4.5 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 61.9 | |||||
9-Day RSI | 42.9 | |||||
14-Day RSI | 37.01 | |||||
6-1 Month Momentum % | -40 | |||||
12-1 Month Momentum % | -53.33 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.08 | |||||
Quick Ratio | 0.08 | |||||
Cash Ratio | 0.02 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.3 | |||||
Shareholder Yield % | 54.08 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -355.16 | |||||
ROA % | -28.07 | |||||
ROIC % | -97.37 | |||||
ROC (Joel Greenblatt) % | 470 | |||||
ROCE % | -280.59 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | 46.57 | |||||
EV-to-EBITDA | 46.57 | |||||
EV-to-FCF | -4.65 | |||||
Earnings Yield (Greenblatt) % | 2.15 | |||||
FCF Yield % | -21.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cambium Bio Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil A$) | |||
EPS (TTM) (A$) | -0.16 | ||
Beta | -1.63 | ||
Volatility % | 201.64 | ||
14-Day RSI | 37.01 | ||
14-Day ATR (A$) | 0.007189 | ||
20-Day SMA (A$) | 0.37075 | ||
12-1 Month Momentum % | -53.33 | ||
52-Week Range (A$) | 0.3 - 1.6 | ||
Shares Outstanding (Mil) | 6.13 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cambium Bio Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cambium Bio Ltd Stock Events
Event | Date | Price(A$) | ||
---|---|---|---|---|
No Event Data |
Cambium Bio Ltd Frequently Asked Questions
What is Cambium Bio Ltd(ASX:CMB)'s stock price today?
The current price of ASX:CMB is A$0.36. The 52 week high of ASX:CMB is A$1.60 and 52 week low is A$0.30.
When is next earnings date of Cambium Bio Ltd(ASX:CMB)?
The next earnings date of Cambium Bio Ltd(ASX:CMB) is .
Does Cambium Bio Ltd(ASX:CMB) pay dividends? If so, how much?
Cambium Bio Ltd(ASX:CMB) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |